Authors : Dr. C. Pandian; A. Gowtham; M. Gunaseelan; B. Pooja; D. Praveen Kumar; Keerthana M.; Subhalakshmy R.; Priyadharshini M.; Bhavani M.

Volume/Issue : Volume 11 - 2026, Issue 9 - September

Google Scholar : https://tinyurl.com/3fpcvnf9

DOI : https://doi.org/10.38124/ijisrt/26sep1306

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Objective: This work was conducted to prepare and characterize a Modafinil-nicotinic acid cocrystal loaded mouth dissolving film (MDF) through formulation-optimization approach.  Methods: Modafinil and nicotinic acid were mixed in a 1:1 molar ratio and characterized in terms of aqueous solubility, FTIR, powder x-ray diffraction (PXRD) and SEM analysis. The cocrystal was prepared in HPMC E5 films by solvent casting method. Variables including HPMC E5, PEG 400 and crospovidone were studied using three-factor three level BoxBehnken design with disintegration time as the main response variable. Optimized MDF was evaluated in terms of appearance, weight variation, folding endurance, surface pH, drug content, disintegration time, in-vitro dissolution and release kinetics.

Keywords : Modafinil; Nicotinic Acid; Pharmaceutical Cocrystal; Mouth Dissolving Film; HPMC E5; PEG 400; Crospovidone; Box–Behnken Design; Dissolution Kinetics.

References :

1. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950-2967. doi:10.1021/cg900129f.
2. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm. 2011;419(1-2):1-11. doi:10.1016/j.ijpharm.2011.07.037.
3. Ghosh T, Juturu T, Nagar SN, Kamath S. Cocrystals of Modafinil-Nicotinic Acid: A Novel Cocrystal for Enhanced Bioavailability. Proc. 2021;62(1):12. doi:10.3390/proceedings2020062012.
4. Kumar R, Sheela M, Sachdeva M. Formulation and evaluation of orodispersible tablets containing co-crystals of Modafinil. J Drug Deliv Ther. 2022;12(5-S):82-89. doi:10.22270/jddt.v12i5-S.5634.
5. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021;11(8):2537-2564. doi:10.1016/j.apsb.2021.03.030.
6. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101-125. doi:10.1016/j.ijpharm.2012.10.043.
7. US Food and Drug Administration. Regulatory Classification of Pharmaceutical Co-Crystals: Guidance for Industry. Silver Spring, MD: FDA; 2018.
8. Jayasankar A, Somwangthanaroj A, Shaikh R, Rodríguez-Hornedo N. Cocrystal formation during co-grinding and storage: phase behavior and mechanisms. Pharm Res. 2006;23:2381-2392.
9. Sarma B, Chen J, His A, Myerson AS. Pharmaceutical cocrystals: an emerging approach to physical property modification. Cryst Growth Des. 2011;11(12):5930-5941.
10. Kale DP, Zode SS, Bansal AK. Challenges in translational development of pharmaceutical cocrystals. J Pharm Sci. 2017;106(2):457-470. doi:10.1016/j.xphs.2016.10.021.
11. McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs. 1998;9(4):311-324. doi:10.2165/00023210-199809040-00006.
12. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.
13. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349-364.
14. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. doi:10.1517/17425247.2011.553217.
15. Krampe R, Sieber D, Finke JH, et al. Oromucosal film preparations: points to consider for patient centricity and manufacturing processes. Expert Opin Drug Deliv. 2016;13(9):1279-1293.
16. Scarpa M, Stegemann S, Hsiao WK, Pichler H, Gaisford S, Bresciani M, et al. Orodispersible films: towards drug delivery in special populations. Int J Pharm. 2017;523(1):327-335. doi:10.1016/j.ijpharm.2017.03.018.
17. Gupta MS, Kumar TP, Gowda DV, Rosenholm JM. Orodispersible films: conception to quality by design. Adv Drug Deliv Rev. 2021;178:113983. doi:10.1016/j.addr.2021.113983.
18. Salawi A. An insight into preparatory methods and characterization of orodispersible film—A review. Pharmaceuticals. 2022;15(7):844. doi:10.3390/ph15070844.
19. Morath B, Sauer S, Zaradzki M, Wagner AH. Orodispersible films—Recent developments and new applications in drug delivery and therapy. Biochem Pharmacol. 2022;200:115036. doi:10.1016/j.bcp.2022.115036.
20. Ferlak J, Guzenda W, Osmałek T. Orodispersible films—Current state of the art, limitations, advances and future perspectives. Pharmaceutics. 2023;15(2):361. doi:10.3390/pharmaceutics15020361.
21. Khan QUA, Siddique MI, Sarfraz M, Rehman K, Sohail MF, Katas H. Oral dispersible films from product development to end-user acceptability: a review. Crit Rev Ther Drug Carrier Syst. 2022;39(1):33-64. doi:10.1615/CritRevTherDrugCarrierSyst.2021036885.
22. Nowak M, et al. ‘Success depends on your backbone’—about the use of polymers as essential materials forming orodispersible films. Materials (Basel). 2021;14(17):4872. doi:10.3390/ma14174872.
23. Senta-Loys Z, Bourgeois S, Pailler-Mattei C, Agusti G, Briançon S, Fessi H. Formulation of orodispersible films for paediatric therapy: investigation of feasibility and stability for tetrabenazine as drug model. J Pharm Pharmacol. 2017;69(5):582-592. doi:10.1111/jphp.12627.
24. Senta-Loys Z, Bourgeois S, Valour JP, Briançon S, Fessi H. Orodispersible films based on amorphous solid dispersions of tetrabenazine. Int J Pharm. 2017;518(1-2):242-252. doi:10.1016/j.ijpharm.2016.12.036.
25. Foo WC, Khong YM, Gokhale R, Chan SY. A novel unit-dose approach for the pharmaceutical compounding of an orodispersible film. Int J Pharm. 2018;539(1-2):165-174. doi:10.1016/j.ijpharm.2018.01.047.
26. Zaki RM, Alfadhel M, Seshadri VD, Albagami F, Alrobaian M, Tawati SM, et al. Fabrication and characterization of orodispersible films loaded with solid dispersion to enhance rosuvastatin calcium bioavailability. Saudi Pharm J. 2023;31(1):135-146. doi:10.1016/j.jsps.2022.11.012.
27. Selmin F, Khalid GM, Musazzi UM, Demartin F, Minghetti P, Cilurzo F. Relevance of production method on the physical stability and in vitro biopharmaceutical performances of olanzapine orodispersible film. Int J Pharm. 2021;602:120697. doi:10.1016/j.ijpharm.2021.120697.
28. El-Bary AA, Al Sharabi IA, Haza'a BS. Effect of casting solvent, film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an in vitro/in silico study. Drug Dev Ind Pharm. 2019;45(11):1751-1769. doi:10.1080/03639045.2019.1656733.
29. Maheswari KM, Devineni PK, Deekonda S, Shaik S, Uppala NP, Nalluri BN. Development and evaluation of mouth dissolving films of amlodipine besylate for enhanced therapeutic efficacy. J Pharm (Cairo). 2014;2014:520949. doi:10.1155/2014/520949.
30. Basu B, Mankad A, Dutta A. Methylphenidate fast dissolving films: development, optimization using simplex centroid design and in vitro characterization. Turk J Pharm Sci. 2022;19(3):251-266. doi:10.4274/tjps.galenos.2021.99223.
31. Moonesan M, Ganji F, Soroushnia A, Bagheri F. Fast-dissolving oral films containing dextromethorphan/phenylephrine for sinusitis treatment: formulation, characterization and optimization. Prog Biomater. 2022;11(3):243-252. doi:10.1007/s40204-022-00191-w.
32. Al-Kubati SS, Ahmed MA, Emad NA. Palatable levocetirizine dihydrochloride solid dispersed fast-dissolving films: formulation and in vitro and in vivo characterization. ScientificWorldJournal. 2022;2022:1552602. doi:10.1155/2022/1552602.
33. Weerapol Y, Manmuan S, Chuenbarn T, Limmatvapirat S, Tubtimsri S. Nanoemulsion-based orodispersible film formulation of guava leaf oil for inhibition of oral cancer cells. Pharmaceutics. 2023;15(11):2631. doi:10.3390/pharmaceutics15112631.
34. Yusuf H, Savitri OMN, Al-Khalifi NN, et al. Cellulose- and saccharide-based orally dispersible thin films transform the solid states and dissolution characteristics of poorly soluble curcumin. Adv Pharmacol Pharm Sci. 2024;2024:8596712. doi:10.1155/2024/8596712.
35. Jadach B, Kowalczyk M, Froelich A, et al. Assessment of alginate gel films as the orodispersible dosage form for meloxicam. Gels. 2024;10(6):379. doi:10.3390/gels10060379.
36. Özcan-Bülbül E, Kalender Y, Bal-Öztürk A, Üstündağ-Okur N. Preparation and in vitro evaluation of montelukast sodium-loaded 3D printed orodispersible films for the treatment of asthma. AAPS PharmSciTech. 2024;25(7):218. doi:10.1208/s12249-024-02938-z.
37. Haider SEB, Desai S, Shahiwala AF. Enhanced solubility and rapid delivery of vitamin D3 via Captisol® inclusion complex in mouth-dissolving films. Adv Pharmacol Pharm Sci. 2025;2025:7621311. doi:10.1155/adpp/7621311.
38. Khobragade DS, Goud UBG, Prakash JSV, Pranav Kumar AVR, Sreenivas Reddy GR, Potbhre M. Formulation and evaluation of polymer based, rapid onset, patient friendly, oral film of domperidone maleate. World J Pharm Sci. 2016;4(1):115-122.
39. Joshi P, Patel H, Patel V, Panchal R. Formulation development and evaluation of mouth dissolving film of domperidone. J Pharm Bioallied Sci. 2012;4(Suppl 1):S108-S109. doi:10.4103/0975-7406.94159.
40. Reuther M, Rollet N, Debeaufort F, Chambin O. Orodispersible films prepared by hot-melt extrusion versus solvent casting. Int J Pharm. 2025;675:125536. doi:10.1016/j.ijpharm.2025.125536.
41. Mann GS, Ramakrishnan M, Pakkam ML, Sufiyan N, Kukadiya R, Girigosavi KB. An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy. Sleep Med X. 2026;11:100185. doi:10.1016/j.sleepx.2026.100185.
42. Broughton RJ, Fleming JAE, George CFP, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444-451. doi:10.1212/WNL.49.2.444.
43. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54(5):1166-1175. doi:10.1212/WNL.54.5.1166.
44. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med. 2000;1(3):231-243. doi:10.1016/S1389-9457(00)00031-9.
45. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, Grebow PE. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39(1):30-40. doi:10.1177/00912709922007534.
46. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154. doi:10.1001/jama.2009.351.
47. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329(2):738-746. doi:10.1124/jpet.108.146142.
48. Scammell TE, Matheson J. Modafinil: a novel stimulant for the treatment of narcolepsy. Expert Opin Investig Drugs. 1998;7(1):99-112. doi:10.1517/13543784.7.1.99.
49. Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139. doi:10.3389/fneur.2013.00139.
50. Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):RA177-RA186.
51. Zhu S, Hong M, Liu C, Pei Y. Application of Box-Behnken design in understanding the quality of genistein self-nanoemulsified drug delivery systems and optimizing its formulation. Pharm Dev Technol. 2009;14(6):642-649. doi:10.3109/10837450902882385.
52. Elbary AA, Aboelwafa AA, Al Sharabi IM. Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design. AAPS PharmSciTech. 2011;12(4):1454-1464. doi:10.1208/s12249-011-9708-9.
53. Cho HJ, Lee DW, Marasini N, Poudel BK, Kim JH, Ramasamy T, et al. Optimization of self-microemulsifying drug delivery system for telmisartan using Box-Behnken design and desirability function. J Pharm Pharmacol. 2013;65(10):1435-1446. doi:10.1111/jphp.12115.
54. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-133. doi:10.1016/S0928-0987(01)00095-1.
55. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-223.
56. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50(10):874-875. doi:10.1002/jps.2600501018.
57. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35. doi:10.1016/0378-5173(83)90064-9.
58. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263-271. doi:10.1208/s12248-010-9185-1.
59. Aulton ME, Taylor KMG, editors. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Edinburgh: Elsevier; 2018.
60. Adejare A, editor. Remington: The Science and Practice of Pharmacy. 23rd ed. London: Pharmaceutical Press; 2020.